HERON THERAPEUTICS, INC. /DE/
HERON THERAPEUTICS, INC. /DE/ (HRTX): 18 pipeline candidates · 4 upcoming catalysts · ~193 mo cash runway · 17 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
193.1 months
D/E 25.95
Lead: Approved
18 candidates
4 upcoming, next in ~1689d
N/A
A transparent, data-derived signal for HERON THERAPEUTICS, INC. /DE/across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$74.1M
Cash
$26.1M
Quarterly Burn
$1.5M
Runway
193.1 mo
Revenue
$34.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| apf530 | Phase 3 |
| aponvie | Approved |
| aprepitant injectable emulsion | Phase 2 |
| bupivicaine hcl | Phase 3 |
| chemotherapy | Phase 3 |
| cinvanti | Approved |
| fosaprepitant | Phase 3 |
| htx-002 | Phase 3 |
| htx-009 | Phase 3 |
| htx-011 | Phase 3 |
Showing 10 of 18 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
165
Total value held
$97.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 15,620,658 | $12.5M |
| clearline capital lp | 12,235,239 | $9.8M |
| blackrock, inc. | 10,106,422 | $8.1M |
| orbimed advisors llc | 9,816,940 | $7.9M |
| millennium management llc | 7,630,527 | $6.1M |
| tang capital management llc | 6,250,000 | $5.0M |
| palisade capital management, lp | 6,140,639 | $4.9M |
| congress park capital llc | 4,032,737 | $3.2M |
| geode capital management, llc | 4,010,087 | $3.2M |
| state street corp | 3,843,672 | $3.1M |
Showing top 10 of 165 institutional holders of HERON THERAPEUTICS, INC. /DE/. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in HERON THERAPEUTICS, INC. /DE/'s pipeline?
HERON THERAPEUTICS, INC. /DE/ (HRTX) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HERON THERAPEUTICS, INC. /DE/'s lead drug candidate?
HERON THERAPEUTICS, INC. /DE/'s most advanced tracked candidate is apf530 (Phase 3) for Nausea and Vomiting; Chemotherapy-induced Nausea and Vomiting.
What is HERON THERAPEUTICS, INC. /DE/'s next catalyst?
HERON THERAPEUTICS, INC. /DE/'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 " — expected February 1, 2031.
What is HERON THERAPEUTICS, INC. /DE/'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HERON THERAPEUTICS, INC. /DE/ has approximately 193.1 months of cash runway.
What is HERON THERAPEUTICS, INC. /DE/'s market capitalization?
HERON THERAPEUTICS, INC. /DE/'s market capitalization is approximately $74.1M.
Get the full picture on HERON THERAPEUTICS, INC. /DE/
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.